Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Merck to buy antibody-drug conjugate developer VelosBio

by Ryan Cross
November 8, 2020 | A version of this story appeared in Volume 98, Issue 43

 

Merck & Co. will pay $2.75 billion to acquire the private San Diego–based cancer firm VelosBio, which is developing antibody drugs that target tyrosine kinase–like orphan receptor 1 (ROR1). VelosBio’s most advanced candidate is an antibody-drug conjugate (ADC) that targets ROR1—found on some cancer cells but not healthy adult cells—and unleashes a toxic agent called monomethyl auristatin E. Three approved ADCs use the same toxic agent. VelosBio began a Phase 2 trial of its ADC in October. The firm also has a preclinical bispecific antibody that targets ROR1 and recruits immune cells to destroy the tumor.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.